Few drugs in recent memory have crossed from clinic to culture as fast as GLP-1 receptor agonists. This class of medicines was developed to improve blood-sugar control in type 2 diabetes, then was shown in randomised trials to drive substantial weight loss. Semaglutide — the agent behind most of the trial evidence discussed below, and the one this article focuses on — now holds separate European authorisations for each of those two uses. These are prescription-only medicines, referred to here by their generic names only. Omniwo does not supply, prescribe, endorse or promote them; this article is educational rather than promotional, and nothing in it is an encouragement to seek a prescription or to start, stop or change any medication — those are decisions for you and a qualified prescriber. What it does is review what the trial evidence actually shows, and does not show, about whether GLP-1 drugs belong in the longevity conversation.
The answer, as of mid-2026, is layered. In the populations actually studied — people who already had cardiovascular disease, type 2 diabetes or chronic kidney disease — large randomised trials reported fewer cardiovascular and kidney events in the treatment arm than in the placebo arm. Whether these metabolic improvements might translate into measurably slower biological ageing remains an open question — the available trial evidence to date was gathered in people with type 2 diabetes or, in the case of SELECT, in people with established cardiovascular disease and overweight or obesity, and to our knowledge, as of mid-2026, no completed trial has tested whether GLP-1 drugs extend lifespan or healthspan in otherwise healthy adults. Meanwhile, the trade-offs — particularly lean-mass loss — deserve the same attention as the benefits.
What the large trials actually found
SELECT: cardiovascular outcomes in adults without diabetes
The strongest longevity-adjacent signal comes from SELECT, a randomised, placebo-controlled trial of 17,604 adults aged 45 and over who had established cardiovascular disease and overweight or obesity but no diabetes. Participants were enrolled across 804 sites in 41 countries and followed for a median of approximately 40 months. Once-weekly semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal heart attack and non-fatal stroke by 20% compared with placebo (hazard ratio 0.80, 95% CI 0.72–0.90).
This is a genuinely large, well-powered result, and the population is the reason it matters: every participant already had established cardiovascular disease, alongside overweight or obesity, and none had diabetes. The effect was accompanied by clinically significant weight reduction at the trial's prespecified assessment points. What makes it notable is the population: a dedicated cardiovascular-outcomes trial of a weight-management medication, run in people whose cardiometabolic risk came from established cardiovascular disease and excess weight rather than from diabetes.
FLOW: kidney outcomes in diabetes with CKD
The FLOW trial enrolled 3,533 adults with type 2 diabetes and chronic kidney disease. Semaglutide reduced the composite kidney endpoint (sustained eGFR decline, kidney failure, renal death or cardiovascular death) by 24% (HR 0.76, 95% CI 0.66–0.88) and also reported a 20% reduction in all-cause mortality (HR 0.80, 95% CI 0.67–0.95). That mortality result was a secondary endpoint rather than the trial's primary question, so it is best read as supportive of the kidney finding rather than as standalone proof of a survival benefit. The trial was stopped early for efficacy after a median follow-up of 3.4 years.
Pooled evidence: a mortality signal across the class
A systematic review and meta-analysis pooling data from eight large cardiovascular outcome trials of GLP-1 receptor agonists in people with type 2 diabetes found a reduction in all-cause mortality and in major adverse cardiovascular events across the drug class. The meta-analysis included trials of liraglutide, semaglutide, dulaglutide and other GLP-1 receptor agonists. It is worth being precise about what "pooled" means here: the mortality reduction is a summary estimate across all eight trials, and results varied between them — several individual trials were not on their own statistically significant for mortality. The direction of effect across multiple drugs is notable — but every participant in this pooled analysis had type 2 diabetes. The mortality benefit is demonstrated in high-risk groups, not in healthy adults seeking to slow ageing.
Evidence rating: STRONG for cardiovascular and kidney outcomes in people with obesity plus existing cardiometabolic disease. For all-cause mortality in healthy adults without disease, the evidence remains EMERGING: we are not aware of a completed trial that has tested this directly.
Beyond the heart: the liver signal
One agent in this class has also been tested directly against liver disease. In a phase 2, randomised, double-blind, placebo-controlled trial, daily subcutaneous semaglutide achieved resolution of non-alcoholic steatohepatitis (NASH) — the aggressive, inflammatory form of fatty liver disease — in 59% of patients at the highest dose (0.4 mg daily), compared with 17% on placebo. The trial enrolled 320 patients with biopsy-confirmed NASH and fibrosis stages F1–F3, and the improvements in liver histology were accompanied by reductions in liver enzymes including ALT. That is a single phase 2 trial, of one drug, in one narrowly defined patient group — it is not evidence that GLP-1 receptor agonists as a class improve liver health in general.
Fatty liver disease is nonetheless common enough for the finding to matter. A meta-analysis of 86 studies covering 8,515,431 people across 22 countries estimated global prevalence at 25.24% (95% CI 22.10–28.65), and among those affected reported obesity in 51.34%, type 2 diabetes in 22.51% and metabolic syndrome in 42.54%. That overlap with metabolic dysfunction is what makes the trial result clinically relevant — though it remains specific to people with biopsy-confirmed liver disease, not a general "liver rejuvenation" claim for otherwise healthy individuals.
The trade-off: lean-mass loss
Weight loss from any intervention — dietary, surgical, pharmacological — includes some lean tissue alongside fat. The concern with GLP-1 receptor agonists is the proportion of lean tissue lost and the speed at which the weight comes off.
In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight over 68 weeks in adults with overweight or obesity. This is a substantial and rapid reduction. What happens to lean tissue during that reduction varies more than the headlines suggest. The most directly relevant synthesis is a 2024 systematic review by Bikou et al. in Expert Opinion on Pharmacotherapy. According to the review's published abstract, the authors searched PubMed, Elsevier and Google Scholar from 2016 for randomised controlled trials and observational studies of semaglutide in overweight or obese patients, with or without type 2 diabetes, and included six studies with 1,541 adults. They report that "significant weight reductions were observed primarily due to fat mass loss" and that "while the lean mass remained stable in some cases, notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others," with "noteworthy decreases in lean mass … particularly evident in larger trials".
The same abstract notes a counterweight: "the proportion of lean mass relative to total body mass increased, suggesting a positive overall outcome". The studies it pooled differed in dose, duration and in how body composition was measured, so the individual figures are not directly comparable with one another.
Lean tissue includes skeletal muscle, and preserving muscle mass and function becomes increasingly important with age. Rapid pharmacological weight loss that takes a meaningful share of its toll from lean tissue is therefore not a trivial consideration. This is especially relevant for older adults and for anyone not actively working to preserve muscle during the weight-loss period. Anyone considering or already using a GLP-1 drug should discuss lean-mass preservation strategies — including adequate protein intake and an appropriate exercise programme — with their prescribing clinician.
None of this settles the benefit–risk balance in either direction — that is a judgement for a prescriber and their patient, made on the full licensed product information rather than on a summary like this one. What the lean-mass finding does establish is that these are drugs with a genuine trade-off, one that deserves honest monitoring and a considered clinical conversation rather than treatment as a consequence-free shortcut to longevity.
What no trial has shown
It is worth stating plainly what the evidence does not yet support:
- The completed trials enrolled people with existing disease — not healthy adults seeking to slow ageing. The systematic review by Sattar et al. pools outcome trials run exclusively in people with type 2 diabetes; SELECT extends the evidence to people who had established cardiovascular disease and overweight or obesity but not diabetes. Between them, that is the population base. To our knowledge, as of mid-2026, no completed trial has tested whether these drugs extend lifespan or healthspan in people without cardiometabolic disease.
- Biological age has not been a primary endpoint. The endpoints studied in the trials above — cardiovascular events, kidney outcomes, mortality — are disease-oriented rather than ageing-oriented. To our knowledge, as of mid-2026, no completed trial has used a biological-age measure as its primary endpoint. Whether the metabolic improvements from GLP-1 drugs translate into measurably slower biological ageing therefore remains an open research question.
- Regulatory approvals do not include an indication for "longevity use." In the EU, semaglutide is authorised for adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise and, under a separate marketing authorisation, for weight management in adults with obesity (BMI ≥30 kg/m²), or with overweight (BMI ≥27 kg/m²) plus at least one weight-related comorbidity such as dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. Neither authorisation covers slowing ageing in healthy people, and off-label use for that purpose is not supported by trial evidence at this stage.
The trajectory of the evidence is genuinely interesting — consistent reductions in cardiovascular events, kidney benefit, liver improvement and rapid metabolic gains, each measured in a defined trial population. But "interesting trajectory" and "proven longevity intervention" are not the same thing, and the gap between them will be measured in years of ongoing and planned trials in broader populations. Until those results arrive, describing GLP-1 drugs as "longevity drugs" is premature, however suggestive the existing data in high-risk populations may be. The honest summary is that these drugs have strong evidence for reducing cardiovascular and kidney events in people who already have disease — and an open, unanswered question about whether they slow ageing more broadly.
How Omniwo helps you measure this
GLP-1 receptor agonists are prescription medicines — only a doctor can decide whether they are appropriate for you, and Omniwo does not prescribe, supply or endorse any medication. What Omniwo does offer is the measurement layer that can help you and your clinician track whether the metabolic shifts the trials describe are happening in your body.
The Advanced Wellness Check includes HbA1c (a three-month average of blood-sugar control), a full lipid panel, liver markers including ALT, and hs-CRP (a marker of systemic inflammation). These are routine markers of metabolic health, not trial endpoints, and it is worth being clear about the difference. The most direct example of a marker on this panel moving in a trial is the phase 2 NASH study, where liver histology improved alongside reductions in liver enzymes including ALT. It is not the only one: SELECT reported change in body weight — a routine measure anyone can track at home — alongside its cardiovascular endpoint. FLOW, by contrast, was built around kidney function and mortality in people with type 2 diabetes and chronic kidney disease, not around a routine biomarker panel at all. The distinction that matters is what those trials were built to prove: their primary and confirmatory secondary endpoints were clinical events, deaths and kidney function, not movement across a routine biomarker panel. So this panel tells you how your own metabolic numbers are moving; it does not reproduce a trial result.
Monitoring the trade-off matters too. If you are losing weight on a GLP-1 drug, pairing blood work with activity data can help you and your clinician see the full picture. Omniwo reads training load, strain and recovery data from WHOOP and Strava alongside your blood markers — so you can check whether your metabolic numbers are improving while you maintain an active training programme.
If you and your clinician decide to track metabolic markers during GLP-1 therapy, a baseline-then-retest approach can show whether your numbers are moving in the direction the trials describe. Omniwo's re-testable model fits that pattern: take a baseline, change an input, re-test, and track the trend over time. The goal is not to replace your doctor's judgement but to give you both a shared, objective set of numbers to work from — measure and track, then discuss what the results mean together.
Omniwo's tests and content are for wellness and educational insight. They are not a medical device, do not diagnose, treat, cure or prevent any disease, and do not replace advice from a qualified healthcare professional.
Sources
-
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563 (PMID: 37952131)
-
Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024;391(2):109–121. doi:10.1056/NEJMoa2403347 (PMID: 38785209)
-
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes & Endocrinology. 2021;9(10):653–662. doi:10.1016/S2213-8587(21)00203-5 (PMID: 34425083)
-
Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021;384(12):1113–1124. doi:10.1056/NEJMoa2028395 (PMID: 33185364)
-
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 (PMID: 33567185)
-
Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opinion on Pharmacotherapy. 2024;25(5):611–619. doi:10.1080/14656566.2024.2343092 (PMID: 38629387)
-
European Medicines Agency. Semaglutide — European Public Assessment Report: authorised therapeutic indication, type 2 diabetes. ema.europa.eu/en/medicines/human/EPAR/ozempic
-
European Medicines Agency. Semaglutide — European Public Assessment Report: authorised therapeutic indication, weight management. ema.europa.eu/en/medicines/human/EPAR/wegovy
-
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease — meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431 (PMID: 26707365)
This article is educational and not medical advice. See our medical disclaimer.